Neuland Labs reported an in-line quarter with 11.4% YoY revenue growth, but profitability was impacted by product mix volatility. Management attributed the lower EBITDA and gross margins to shipment delays of two specific high-margin products, terming the quarter's margin profile an 'aberration'. The company is in a ramp-up phase for new CDMO capacities, leading to temporary high working capital, which is expected to normalize. While cautious on near-term guidance due to the 'lumpy' nature of the business, management reiterated confidence in achieving ~30% EBITDA margins in the long run and highlighted significant traction in the high-potential peptide segment.
vs Q4 FY26
Notable Quotes from the Call
Most Confident Moment
Reiterating that the business is capable of ~30% EBITDA margins and has a 'preordained' growth path for the next 2-3 years.
Least Confident Moment
Explicitly stating 'I just want to be very cautious not to kind of give any sort of guidance or input' when asked about the Q4/FY26 outlook.
| Metric | Value | YoY |
|---|---|---|
| Total Income | ₹447.8 Cr | +11.4% YoY |
| EBITDA Margin | 19% | — |
| Adjusted EBITDA Margin | 21% | — |
| Profit Before Tax (PBT) | ₹54.3 Cr | -24.4% YoY |
| EPS | ₹31.5 | — |
| Working Capital | 145 days | — |
| Metric | Latest | Trend |
|---|---|---|
| Total Income(crores) | 447.8 | |
| EBITDA(crores) | 156.9 | |
| EBITDA Margin | 19% | |
| Gross Margin | 60.1% | |
| PAT(crores) | 96.5 | |
| EPS(Rs) | 31.5 |
| Category | Target | Priority |
|---|---|---|
| Profitability | EBITDA Margin Capability→~30% | Medium |
| Growth | Decadal Growth Aspiration→20-plus CAGR | Low |
| Pipeline | Peptide Commercial Arrangement→at least 1 | Low |
| Operations | Inventory Days Normalization→~90 days | Medium |
| Operations | Paliperidone Shipment Issue Resolution→Resolved | Medium |
| Severity | Risk |
|---|---|
high | Product Mix Volatility The quarter's lower margins were a direct result of shipment timing for two high-margin products, highlighting significant near-term earnings risk. Management |
medium | Lumpy Revenue Recognition Ramp-up of new capacities and large value CMS shipments are inherently uneven, making quarterly forecasting difficult. Management |
medium | Elevated Working Capital Inventory has increased to 145 days to support future growth, temporarily straining cash flows. Management expects this to normalize. Analyst |
medium | Customer-side Operational Issues Shipments of Paliperidone were delayed due to issues at the customer's end, an external risk factor beyond Neuland's direct control. Management |
Areas of Evasion(1)
Neuland Labs reported a total income of ₹447.8 crores for Q3 FY26, an 11.4% YoY increase. However, profitability was under pressure, with the gross margin contracting to 52.1% and the reported EBITDA margin at 19%. Management was transparent in attributing this to two key factors: the non-shipment of a high-margin CMS product and a delay in shipments of the specialty GDS product, Paliperidone, due to customer-side issues. They characterized this quarter's margin performance as an 'outlier' and an 'aberration', suggesting the trend seen in previous quarters is more representative.
The company is in a crucial phase of ramping up new capacities. The expanded capacity for a key CDMO contract in Unit 3 has started shipping volumes, but the ramp-up is still in its early stages and will take another one to two quarters to mature. Similarly, a newly commercialized CMS molecule saw initial, small shipments at the end of Q3, with the bulk remaining to be shipped. Management emphasized the 'lumpy' nature of these large-value shipments, which contributes to quarter-on-quarter volatility.
Management highlighted significant strategic progress in the peptide space, a key future growth driver. They noted engagement with 5-6 innovators on new peptide projects. The long-term goal is to leverage the new R&D campus in Genome Valley and the large-scale manufacturing capacity to become a key partner for innovators. A tangible target mentioned was to secure at least one commercial manufacturing agreement for a peptide NCE (New Chemical Entity) by FY27.
Working capital days increased to 145, driven by a conscious build-up of inventory to support the anticipated revenue ramp-up. The CFO described this as a 'transition period' and expects inventory days to normalize back to around 90 days over the next three quarters. The company continues its planned investment cycle, with a cash outflow of ₹254 crores towards capex in 9MFY26. Despite this, the balance sheet remains strong with a net cash position of ₹202.6 crores.
Despite near-term caution, management projected strong long-term prospects. They stated that growth for the next 2-3 years is 'kind of preordained' by the existing portfolio of commercialized and ramping-up products. They also reaffirmed that the ~30% EBITDA margin achieved in FY24 is a 'fair representation' of the business's true potential. Looking further ahead, management shared an aspirational goal of achieving a 20%+ CAGR over the decade from 2026 to 2036, driven by strategic initiatives like peptides and a focus on higher-value molecules.